APGE Apogee Therapeutics, Inc.
USHealthcareAs of 2026-09-04 16:00
Why APGE matters now
Apogee Therapeutics, Inc. (APGE) is a US stock in Healthcare. The latest InvestLog snapshot shows $135.07 with +0.00% on the session and $8.36B in market capitalization; recent performance reads 1-month +15.47% and YTD +19.74%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-74.1M, and EPS of $-1.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.2%.
The latest indexable market news headline is "AbbVie Completes Acquisition of Apogee Therapeutics" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $116.00; recent insider activity includes HENDERSON MICHAEL THOMAS filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.01
P/S
0.00
EV/EBITDA
-18.89
DCF Value
$2.09
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.6%
ROA
-21.2%
ROIC
-24.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-74.1M | $-1.06 |
| Q4 2025 | $0.00 | $-69.4M | $-1.03 |
| FY 2025 | $0.00 | $-255.8M | $-4.22 |
| Q3 2025 | $0.00 | $-65.0M | $-1.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$113.67
Target (Median)
$116.00
Target Range
$81.00 - $140.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.62
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.